Abstract:Abstract Sarcoidosis is a multisystem granulomatous disorder of uncertain aetiology, manifesting with cutaneous features in one-third of affected individuals. We retrospectively reviewed medical records of patients with a clinical diagnosis of cutaneous sarcoidosis in dermatology departments within our region. Sixty-five patients were identified. The mean age at presentation was 49 years (range 28–75), with increased prevalence in women (44, 68%). Twenty-six patients (40%) had localized disease affecting a single anatomical location, three of which were within tattoos. Thirty-nine (60%) had involvement of at least two anatomical locations. Limbs were the most frequently affected site (41). Other affected areas were the face (32), torso (25), scalp (9) and neck (5). Plaques were the most common morphology, seen in 26 cases, followed by papules (23), nodules (23), patches (6), erythema nodosum (4), annular (3), ulceration (3) and subcutaneous nodules (3). The colours of lesions were erythematous (37), yellow–orange–brown (22), violaceous (9) and skin coloured (5). All patients had biopsy-proven noncaseating granulomas; 60 patients had this confirmed on skin biopsy and five patients from other organs. In total, 41 patients (63%) had systemic sarcoidosis. Twenty-four of those with systemic sarcoid osis (59%) had cutaneous signs as their first presentation of sarcoid osis. Pulmonary sarcoidosis was diagnosed in 36 (55%), with relevant findings on chest X-ray, computed tomography of the thorax and/or pulmonary function tests. Of these, 22 patients did not report respiratory symptoms. Other organs involved were eye (6), joint (6), extrapulmonary lymph nodes (5), liver (4), cardiac (3), central nervous system (2) and renal (2). Lymphopenia was detected in 14 (22%) and anaemia in six (9%) patients. Twenty-three (35%) had elevated serum angiotensin-converting enzyme (ACE) levels. Four patients with elevated serum ACE levels did not have systemic sarcoidosis. Twenty-two of 41 patients with systemic sarcoidosis did not have elevated serum ACE levels. Complete resolution of skin lesions was observed in 32 patients. Management included watchful monitoring (8), potent or superpotent topical steroids (11), short courses of prednisolone (3), antimalarials (3), intralesional steroids (2), methotrexate (1), tofacitinib (1), and treatments initiated for systemic sarcoidosis including long-term prednisolone (3) and adalimumab (1). Our study highlights a lack of correlation between clinical features of cutaneous disease and systemic involvement. We found no association between biochemical profile and severity of sarcoidosis, or disease progression. It underscores the importance of maintaining a high index of suspicion and conducting thorough investigations for early detection of extracutaneous disease, as patients with extensive systemic sarcoidosis may be asymptomatic.

Predicting the risk of pulmonary deterioration in sarcoidosis

Pulmonary sarcoidosis: differences in lung function change over time

Unraveling genetic mysteries: phenotype-shaping profiles in chronic sarcoidosis

Prognosis of sarcoidosis and factors affecting prognosis

Lung mechanics and their relationship to lung volumes in pulmonary sarcoidosis

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis

Lymphocyte Subsets and Pulmonary Nodules to Predict the Progression of Sarcoidosis

The Association Between Air Pollution and Lung Function in Sarcoidosis and Implications for Health Disparities

Risk Factors of Relapse in Pulmonary Sarcoidosis Treated with Corticosteroids

The Short- and Long-Term Impact of Pulmonary Rehabilitation in Subjects with Sarcoidosis: A Prospective Study and Review of the Literature

FOXP3+ regulatory T cells are associated with the severity and prognosis of sarcoidosis

Myocardial contractile patterns predict future cardiac events in sarcoidosis

Phenotypes of organ involvement in sarcoidosis

Meta-analysis of [18F]FDG-PET/CT in pulmonary sarcoidosis

High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study

Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort

High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities

In sarcoidosis trials, time also matters

Recent advances in sarcoidosis

P111 A retrospective analysis of cutaneous sarcoidosis

Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden